company background image
T5O

CytoTools XTRA:T5O Stock Report

Last Price

€3.89

Market Cap

€15.7m

7D

-2.5%

1Y

-78.1%

Updated

22 May, 2022

Data

Company Financials
T5O fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

T5O Stock Overview

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies.

CytoTools Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for CytoTools
Historical stock prices
Current Share Price€3.89
52 Week High€18.35
52 Week Low€3.40
Beta0.84
1 Month Change-5.12%
3 Month Change6.58%
1 Year Change-78.15%
3 Year Change-69.61%
5 Year Change-70.46%
Change since IPO-73.08%

Recent News & Updates

Jul 29
Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

May 12
CytoTools AG (ETR:T5O): Are Analysts Optimistic?

CytoTools AG (ETR:T5O): Are Analysts Optimistic?

With the business potentially at an important milestone, we thought we'd take a closer look at CytoTools AG's ( ETR:T5O...

Shareholder Returns

T5ODE BiotechsDE Market
7D-2.5%4.3%-0.09%
1Y-78.1%-31.4%-12.9%

Return vs Industry: T5O underperformed the German Biotechs industry which returned -31.4% over the past year.

Return vs Market: T5O underperformed the German Market which returned -12.9% over the past year.

Price Volatility

Is T5O's price volatile compared to industry and market?
T5O volatility
T5O Average Weekly Movement13.1%
Biotechs Industry Average Movement8.1%
Market Average Movement6.4%
10% most volatile stocks in DE Market10.6%
10% least volatile stocks in DE Market3.5%

Stable Share Price: T5O is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: T5O's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200010Mark-André Freyberghttps://cytotools.de

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective.

CytoTools Fundamentals Summary

How do CytoTools's earnings and revenue compare to its market cap?
T5O fundamental statistics
Market Cap€15.67m
Earnings (TTM)-€1.75m
Revenue (TTM)€22.28k

703.4x

P/S Ratio

-9.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
T5O income statement (TTM)
Revenue€22.28k
Cost of Revenue€0
Gross Profit€22.28k
Other Expenses€1.77m
Earnings-€1.75m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin100.00%
Net Profit Margin-7,836.80%
Debt/Equity Ratio0.0%

How did T5O perform over the long term?

See historical performance and comparison

Valuation

Is CytoTools undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


0.73x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate T5O's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate T5O's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: T5O is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: T5O is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate T5O's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: T5O is good value based on its PB Ratio (0.7x) compared to the DE Biotechs industry average (1.5x).


Future Growth

How is CytoTools forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


77.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytoTools has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has CytoTools performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-11.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: T5O is currently unprofitable.

Growing Profit Margin: T5O is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: T5O is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.

Accelerating Growth: Unable to compare T5O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: T5O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: T5O has a negative Return on Equity (-8.19%), as it is currently unprofitable.


Financial Health

How is CytoTools's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: T5O's short term assets (€855.5K) exceed its short term liabilities (€257.3K).

Long Term Liabilities: T5O's short term assets (€855.5K) exceed its long term liabilities (€2.6K).


Debt to Equity History and Analysis

Debt Level: T5O is debt free.

Reducing Debt: T5O had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if T5O has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if T5O has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is CytoTools's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate T5O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate T5O's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if T5O's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if T5O's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as T5O has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Mark-André Freyberg

22.33yrs

Tenure

Dr. Mark-André Freyberg co-founded CytoTools AG in 2000 and serves as Chief Executive Officer since 2000 and had been the Chairman of Management Board until September 30, 2021 and previously also served as...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CytoTools AG's employee growth, exchange listings and data sources


Key Information

  • Name: CytoTools AG
  • Ticker: T5O
  • Exchange: XTRA
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €15.669m
  • Shares outstanding: 4.03m
  • Website: https://cytotools.de

Number of Employees


Location

  • CytoTools AG
  • Klappacher Strasse 126
  • Darmstadt
  • Hessen
  • 64285
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.